A study to establish the diagnostic performance of 18F-fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy (REVELATE)

Recruiting
18 years - 99 years
All
Phase 3
20 participants needed
1 Location

Brief description of study

The research study is being conducted to show how effective an imaging drug called 18F-fluciclovine can be used to image uptake before planned surgery. Fluciclovine is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT). PET scan is for detecting suspected recurrence of brain metastases in adults after radiation therapy. 18F Fluciclovine is a specialized radioactive PET tracer used to image areas where your doctors think either your tumor has come back or there is a change in the area because of the treatment you have received for your cancer. We would like to test whether this type of specialized imaging can help determine if there is active cancer present

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: brain metastases
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, 18 years of age or older, Subjects with solid tumor brain metastases previously treated with radiation therapy

Updated on 04 Aug 2024. Study ID: 844052

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center